potential side effects of glp 1 Adverse GLP-1 Receptor Agonists Glucagon-like Receptor-1 agonists for obesity:

Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, et al

Quick Answer: GLP-1 receptor agonist medications do not appear on standard blood tests, drug screenings, or employment panels

Exposure to allergens, pollutants, or harsh weather conditions can exacerbate skin sensitivity

Monlunabant: A treatment for obesity Developed by Novo Nordisk, Monlunabant is not a GLP-1 receptor agonist at all, but a treatment for obesity

The FDA has a special program called "expanded access" (sometimes called compassionate use) for people who are seriously ill and have run out of options

References Desprs JP